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Several substances are added to plastics, elec-
tronics, textiles, and construction material to
protect against fire. Brominated flame retar-
dants (BFRs) are the cheapest ﬂame retardant
and account for 39% of worldwide ﬂame retar-
dant production (Darnerud et al. 2001; de Wit
2002; Rahman et al. 2001). Polybrominated
diphenyl ethers (PBDEs), a subgroup of BFRs,
were produced at a worldwide annual rate of
40,000 metric tons in 1999 (Rahman et al.
2001). There are three technical products of
PBDEs, each with a different range of bromine
substitution (Darnerud et al. 2001). These
molecules are similar in structure to polychlori-
nated biphenyls (PCBs) and are speciﬁed using
the same numbering scheme (Ballschmitter
and Zell 1980). Their structural similarity to
PCBs, known to have neurotoxic and carcino-
genic action, begs the question of potential
biologic hazards associated with PBDEs.
With the advent of governmental regula-
tions banning their use, the levels of PCBs have
been slowly decreasing in our environment
(Dallaire et al. 2002); on the other hand, the
levels of PBDEs are rapidly increasing (Noren
and Meironyte 2000). PBDEs have been found
in ﬁsh from the Great Lakes and rivers in the
United States (Dodder et al. 2002; Hale et al.
2001; Luross et al. 2002; Manchester-Neesvig
et al. 2001). PBDEs have also been reported in
chickens, seafood, seals, and other aquatic mam-
mals and in human milk, fat, liver, and serum
samples (Booij et al. 2002; Christensen et al.
2002; Darnerud et al. 2001; Huwe et al. 2002;
Jakobsson et al. 2002; Ohta et al. 2002; She et
al. 2002; Sjodin et al. 2001). Examination of
Swedish human milk samples from 1972 to
1997 showed an alarming, exponential increase
in PBDE levels, with a doubling rate of about
5 years (Noren and Meironyte 2000). Similarly,
blood concentrations in pooled samples from
Norway show a 9-fold increase in PBDEs
between 1977 and 1999 (Thomsen et al. 2002).
Given these ﬁndings, the Swedish government
voted to ban some lower brominated formula-
tions of PBDEs by July 2003 (Betts 2002). It
has recently been reported that PBDE levels
in milk samples from Swedish women have
decreased since 1997 (Hooper and She 2002);
whether this trend is due to the voluntary
phase-out of penta-PBDE is not certain.
Concentrations in North America also appear
to be increasing. Levels of congeners found in
the penta-PBDE formulation have been
increasing in ringed seal from the Canadian
Arctic (Ikonomou et al. 2002) and herring gull
eggs from the Great Lakes (Norstrom et al.
2002) since 1981.
Human exposure to PBDEs comes mainly
from ingestion of dietary products, such as
fish and cow’s milk (Darnerud et al. 2001).
Airborne contamination has also been impli-
cated, particularly in the electronics and com-
puter industries (Jakobsson et al. 2002; Sjodin
et al. 1999).
The aim of our study was to determine the
human fetal and maternal serum concentra-
tions of PBDEs in central Indiana. Although
based on only a small sample set, our ﬁndings
indicate that women in Indiana are exposed
to levels even higher than those that war-
ranted banning the use of PBDEs in products
sold in Sweden. This preliminary report indi-
cates that further, large-scale studies will be
needed to assess exposure levels across a
broader population, to identify the sources of
exposure in the United States, and to exam-
ine possible neurodevelopment deﬁcits associ-
ated with high levels of exposure during fetal
development.
Materials and Methods
Clinical materials. Institutional review board
approval was obtained for studies involving
humans. Patients who were older than 18 years,
presenting in labor to Indiana University and
Wishard Memorial County hospitals in
Indianapolis during August–December 2001,
were asked to participate. Pregnancies were full
term, and no other major medical problems
were noted in the mothers. Patients were asked
to fill out a survey to determine age, race,
smoking habits, potential occupational expo-
sures to PBDEs (e.g., working in computer or
electronics manufacturing, repair, or disman-
tling plants), and any other chemical expo-
sures. Body mass index (BMI; kg/m2) was
calculated from the mother’s height, prepreg-
nancy weight, and weight at the time of deliv-
ery. Maternal blood was obtained when the
patient was admitted to the labor and delivery
suite, and fetal blood was obtained from the
umbilical cord vein by syringe after delivery.
The weight and presence of any congenital
defects were noted for each baby.
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Polybrominated diphenyl ethers (PBDEs) are widely used as ﬂame retardants in consumer goods,
such as plastics, electronics, textiles, and construction material. PBDEs have been found in human
milk, fat, and blood samples. Rodent studies indicate that PBDEs may be detrimental to neuro-
development, possibly by lowering thyroid hormone concentrations in blood. In the present study,
we determined concentrations of PBDEs and thyroid hormones in human fetal and maternal serum.
Patients presenting in labor to Indiana University and Wishard Memorial County hospitals in
Indianapolis, who were older than 18 years, were recruited to participate. Twelve paired samples of
maternal and cord blood were obtained and analyzed using gas chromatographic mass spectrometry;
thyroid hormone concentrations were determined by radioimmunoassay. Six congeners of PBDE
were measured in maternal and fetal serum samples. The concentrations of total PBDEs found in
maternal sera ranged from 15 to 580 ng/g lipid, and the concentrations found in fetal samples
ranged from 14 to 460 ng/g lipid. Individual fetal blood concentrations did not differ from the cor-
responding maternal concentrations, indicating that measurement of maternal PBDE blood levels is
useful in predicting fetal exposure; similarly, other reports have shown a high correlation between
PBDE in mother’s milk and fetal exposure. In accord with reports on other biologic samples, the
tetrabrominated PBDE congener BDE-47 accounted for 53–64% of total PBDEs in the serum. The
concentrations of PBDEs found in maternal and fetal serum samples were 20–106-fold higher than
the levels reported previously in a similar population of Swedish mothers and infants. In this small
sample, there was no apparent correlation between serum PBDEs and thyroid hormone concentra-
tions. Our study shows that human fetuses in the United States may be exposed to relatively high
levels of PBDEs. Further investigation is required to determine if these levels are speciﬁc to central
Indiana and to assess the toxic potential of these exposure levels. Key words: brominated diphenyl
ethers, cord blood, human, pregnancy, serum. Environ Health Perspect 111:1249–1252 (2003).
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dure. The extraction of PBDEs from the
serum was based on the method developed
and validated by Hovander et al. (2002) but
was modiﬁed to accommodate our larger sam-
ple sizes. Maternal serum (10 mL) or cord
serum (5 mL) was transferred to a glass vial
and spiked with the internal chlorodiphenyl
ether (CDE) standards 13C12–2,3,3´,4,4´,5-
hexachlorodiphenyl ether (CDE-156) and
13C12–2,2´,3,3´,4,4´,5,5´-octachlorodiphenyl
ether (CDE-194). Hydrochloric acid (2 mL,
6 M) and then 2-propanol (12 mL) were added;
the sample was vortexed after each addition.
Hexane/methyl t-butyl ether (MTBE; 10 mL,
1:1, vol/vol) was added, and the sample was
rotated for 20 min and then centrifuged. The
organic layer was transferred to a new vial, and
the serum was extracted with hexane/MTBE
two more times, once with 10 mL and once
with 5 mL. The three organic fractions were
combined, and a 3-mL aliquot was removed
for gravimetric determination of the lipid mass.
The combined organic fraction was then
exchanged into hexane and reduced in volume
to approximately 5 mL using a rotary evapora-
tor. The hexane, dichloromethane, and H2SO4
came from EM Science (Gibbstown, NJ); the
MTBE and propanol came from Burdick &
Jackson (Muskegon, MI); and the HCl came
from Mallinckrodt (Hazelwood, MO). All of
the organic solvents were of pesticide-analysis
grade.
We removed the lipids by first adding
H2SO4 (2 mL, concentrated) to the extract,
centrifuging, and transferring the organic phase
to a new vial. The sample was washed once
with hexane, and the organic fractions were
combined. The sample was then reduced in
volume to 1 mL with a stream of nitrogen and
loaded onto a 20-cm × 1.9-cm (inner diame-
ter), 1% water-deactivated silica gel column
(Grace Davison, Baltimore, MD). The silica
gel had previously been cleaned using Soxhlet
extraction with dichloromethane for 12 hr fol-
lowed by activation at 120°C for 12 hr. Three
75-mL fractions were collected with the fol-
lowing solvents: hexane, 30% dichloromethane
in hexane, and dichloromethane. The middle
fraction was reduced in volume to 0.5 mL
using a rotary evaporator followed by a nitrogen
stream.
Alumina (ICN Biomedicals, Costa Mesa,
CA) was cleaned and activated for 12 hr at
450°C. The alumina was dry loaded into a
0.5 cm (inner diameter) × 9.5 cm Pasteur
pipette to a height of 6.5 cm and capped with
0.5 cm of anhydrous sodium sulfate. The col-
umn was wetted with hexane, and the sample
was loaded onto the column. Two fractions of
8 mL each were collected: hexane followed by
40% dichloromethane in hexane. The PBDEs
eluted in the second fraction, to which the
PBDE congener BDE-118 was added as a
recovery standard. The sample was reduced in
volume to approximately 20 µL under a
stream of nitrogen before injection into the
gas chromatographic (GC) mass spectrometer.
Instrumental analysis and parameters.
We analyzed the samples on an Agilent 6890
series GC coupled to an Agilent 5973 mass
spectrometer with helium as the carrier gas
(Agilent, Palo Alto, CA). The 2 µL injections
were made in the pulse splitless mode, with a
purge time of 2.0 min. The injection port was
held at 285°C. The GC column was a 60 m ×
250 µm (inner diameter) fused silica capillary
tube coated with DB-5-MS (0.25 µm film
thickness; J&W Scientific, Folsom, CA). A
60-m column was used to ensure separation of
BDE-154 from polybrominated biphenyl 153
(PBB-153). The GC oven temperature pro-
gram was as follows: isothermal at 110°C for
1.90 min, 15°C/min to 180°C, 1.85°C/min
to 300°C, and held at 300°C for 45 min. The
transfer line was held at 285°C. The mass spec-
trometer was operated in electron capture neg-
ative ionization (ECNI) mode using methane
as the buffer gas. Selected ion monitoring
(SIM) of the two bromide ions at m/z 79 and
81 was used to detect the PBDEs. The ions at
m/z 351.9 and 349.9 were used to detect
CDE-156, and ions at m/z 457.8 and 455.8
were used to detect CDE-194. In each case,
the ﬁrst ion was used for quantitation and the
second for confirmation. The compounds
were quantitated using quantitation standards
with known amounts of all the target com-
pounds, internal standards, and recovery stan-
dards. CDE-194 was used to quantitate the
PBDEs; CDE-153 was used to confirm
the match of the retention times of the
compounds in the sample with those in the
standard solution.
Quality control. Three quality control
criteria were used to ensure the correct identi-
ﬁcation of the target compounds: a) The GC
retention times matched those of the standard
compounds; b) the signal-to-noise ratio was
> 3; and c) the isotopic ratio between the
quantitative ion and confirmation ion was
within ±15% of the theoretical value. The
average recovery of the internal standard was
65 ± 5%.
Two procedural blanks were run in paral-
lel with every batch of six samples. The proce-
dural blank consisted of an appropriate
amount of hexane spiked with the internal
standard. The blanks contained only BDE-47
and BDE-99, at average levels of 56 ± 11 pg
and 31 ± 5 pg, respectively. If the average
blank level for either congener was < 30% of
the congener level in the serum sample, the
average blank level was subtracted from the
serum level. If the blank level for either con-
gener was > 30%, that sample was excluded.
This criterion was applied to each BDE con-
gener so that the limits of detection of each
congener varied from 0.01 to 0.19 ng. Six of
the 30 samples analyzed had to be excluded
because of high blanks.
Thyroid hormones. Serum thyroxine (T4)
and triiodothyronine (T3) were measured
in the Analyte Core Facility at Indiana
University School of Medicine, Indianapolis.
Radioimmunoassay kits for total and free T4
and T3 were purchased from Diagnostic
Products Corp. (Los Angeles, CA) and used
according to the manufacturer’s protocols.
Detection limits were 1 µg/dL and 0.02 µg/dL
for total T4 and total T3, respectively; the
detection limits for free T4 and free T3 were
1 ng/dL and 0.06 ng/dL, respectively.
Statistics. A paired t-test analysis was used
to determine whether fetal and maternal
PBDEs differed. In addition, correlations
between maternal and fetal PBDEs and
between PBDEs and BMI, birth weight, or
thyroid hormones were tested using the
Pearson coefﬁcient of determination.
Results
Fifteen paired maternal and fetal samples were
analyzed for PBDE; three pairs of these sam-
ples are not reported because they did not
meet quality control speciﬁcations because of
problems with blank analysis. Of the 12
patients reported, the average age was 26 years
with a range of 18–37 years. The average BMI
at presentation was 36 with a range of 27–56.
None of the mothers reported any work-related
potential for exposure to PBDEs, and all denied
smoking exposure. Infant weights ranged from
3,050 to 4,040 g; no birth defects were docu-
mented. Six different congeners of PBDE were
measured in the serum samples (Table 1). Of
the six congeners detected, BDE-47 accounted
for the majority (53–64%) of all PBDEs;
BDE-99 was the next most abundant congener
at 15–19% (Figure 1). The concentrations of
total PBDEs found in maternal sera ranged
from 15 to 580 ng/g lipid, and the concentra-
tions found in fetal samples ranged from 14 to
460 ng/g lipid. The PBDE concentrations
were highly correlated (r2 = 0.986), exhibiting
no statistical differences between maternal and
fetal blood (Figure 2). All the PBDE congeners
were detected in all the samples except BDE-
154, which was not detected in two of the
samples, and BDE-183, which was not
detected in 20 of the 24 samples. The detec-
tion limits for BDE-154 and BDE-183 were
0.01 and 0.03 ng, respectively.
There was no apparent correlation between
concentrations of PBDEs and any of the clini-
cal parameters. Serum PBDE concentrations
did not vary according to age or BMI, nor was
there any relationship between infant birth
weight and PBDE concentrations. Thyroid
hormones were assayed in 9 of the 12 sample
pairs. Figure 3 shows no apparent correlation
between total PBDEs and T4 concentrations
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tion between PBDEs and either total or free T3
(data not shown).
Discussion
This is the ﬁrst report of PBDE blood levels in
pregnant women and their fetuses from the
United States. We found that total PBDEs var-
ied over an approximate 40-fold range in the
12 pairs of samples analyzed. When compared
with a similar population of Swedish mothers
and newborns (Guvenius et al. 2003), serum
PBDE levels in our study were 20- to 69-fold
higher for maternal blood and 30- to 106-fold
higher for fetal blood. Likewise, the range of
BDE-47 levels we report in women from
Indiana was approximately 20-fold that found
in Norwegian blood samples from 1997–1999
(Thomsen et al. 2002). Moreover, the median
blood levels found in our population indicate
an exposure to PBDEs comparable with that
of Swedish workers considered to have had
direct, work-related exposures (Jakobsson et
al. 2002; Sjodin et al. 1999). In contrast, sam-
ples collected from adult U.S. blood donors in
1988 had sum concentrations of PBDEs that
were much lower (~0.12–0.65 ng/g lipid)
(Sjodin et al. 2001) than the levels we found
in the maternal samples. The reason for the
disparity between our results and those of pre-
vious studies is not positively known; how-
ever, because PBDEs are not manufactured
in Europe, as they are in the United States
(Darnerud et al. 2001), exposure levels may
be lower in Europe. In addition, concentra-
tions of PBDEs in the North American envi-
ronment have increased since 1988 (Ikonomou
et al. 2002; Norstrom et al. 2002). It will
require further investigation to determine
whether the high human concentrations
reported here represent a regional or a national
trend. However, in a review of the currently
available data, Ryan observed that concentra-
tions of PBDEs in breast milk of North
American women were 40–50 times greater
than concentrations previously described in
Swedish breast milk samples (Betts 2002).
Similarly, a recent study of PBDEs in breast
fat of women in San Francisco found concen-
trations averaging 86 ng/g lipid (She et al.
2002). Together with our study, these observa-
tions indicate that women in North America
are exposed to much higher levels of PBDEs
than are European women.
In general, the PBDE congener proﬁle we
found in human serum was similar to that
detected in environmental samples, except that
there is an apparent decrease in the proportion
of BDE-99. In air, BDE-99 accounts for 35%
of the total PBDEs (Strandberg et al. 2001),
whereas in fish it was 27% (Dodder et al.
2002), and in humans it was 15–19% (present
study). This range for BDE-99 is similar to the
range found in other human studies (Hovander
et al. 2002; Sjodin et al. 2001). The lower pro-
portion of BDE-99 may indicate a differential
metabolic degradation of BDE-99 as it goes
through the food chain. In addition, BDE-183
was detected in only 4 of the 24 samples, even
though it is the primary congener in the octa-
BDE technical mixture (Darnerud et al. 2001).
This may be the case because BDE-183, like
BDE-209, has a lower bioavailability compared
with the other lower brominated congeners or
because its low vapor pressure does not facilitate
its atmospheric transport as readily as the other
congeners (Dodder et al. 2002; Strandberg et
al. 2001). On the other hand, relatively high
levels of BDE-183 have been observed in occu-
pationally exposed workers (Sjodin et al. 1999;
Thomsen et al. 2001). It would be interesting
to identify the metabolites of the congeners
present because they have the potential to
behave as endocrine disruptors (Meerts et al.
2000, 2001).
It is apparent that, like PCBs and organo-
chlorine pesticides (Covaci et al. 2002;
DeKoning and Karmaus 2000; Sala et al.
2001; Waliszewski et al. 2000), PBDEs
cross the placenta into the fetal circulation.
Furthermore, our results indicate that all
tetra- through hepta-substituted congeners
have approximately the same potential to
cross the placenta. The high correlation
between maternal and fetal blood levels of
PBDE indicates that measurement of mater-
nal PBDE yields a strong indication of PBDE
exposure of the fetus at the time of birth;
whether this is true at earlier points in gesta-
tion will require additional studies. It is likely
that lipophilic compounds such as PBDEs
move into fetal circulation along with mater-
nal lipids. Experimental analysis of maternal
and fetal blood samples and lipid infusion stud-
ies indicate that there is an inﬂux of lipids from
maternal and placental sources into the fetal cir-
culation (Berghaus et al. 1998; Elphick et al.
1978; Hendrickse et al. 1985). Furthermore,
there is a dramatic mobilization of maternal fat
stores during the third trimester of gestation
(Pipe et al. 1979), a period critical to brain
development (Porterﬁeld 2000); the biologic
significance and bioavailability of PBDEs in
fetal circulation during this period of gestation
have yet to be determined.
PCBs and dioxins are known neurotoxi-
cants, as demonstrated in experimental animal
studies and in humans through epidemiologic
studies (Brouwer et al. 1995; Jacobson et al.
1990). PBDEs are structurally similar to PCBs,
and studies have been performed to assess their
neurotoxic potential. Neonatal and fetal expo-
sure of mice to PBDEs showed a permanent
effect on spontaneous behavior, learning, and
memory (Eriksson et al. 2001, 2002). Thyroid
hormones play an important role in brain devel-
opment, and deﬁciencies in T4 are known to
cause mental delay in humans (Porterﬁeld 2000;
Children’s Health | Maternal–fetal PBDEs
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Table 1. Concentrations (ng/g lipid) of BDE con-
geners in fetal and maternal serum (n = 12).
BDE Fetal Maternal
congener Median Range Median Range
BDE-47 25 8.4–210 28 9.2–310
BDE-99 7.1 2.2–54 5.7 2.4–68
BDE-100 4.1 1.8–91 4.2 1.9–110
BDE-153 4.4 1.0–120 2.9 1.0–83
BDE-154 0.7 0.2–7.2 0.3 0.0–6.1
BDE-183 0 0.0–4.8 0 0.0–2.7
Total PBDEs 39 14–460 37 15–580
Figure 1. Congener proﬁles of PBDE in serum. The
mean level of each congener detected was deter-
mined as a percentage of the total PBDEs present
(mean ± SD, n = 12).
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Figure 2. Total PBDE concentrations in maternal
and fetal blood samples. The sum of all congeners
detected in each sample is presented.
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Figure 3. Thyroid hormone concentrations. The
total (A) and free (B) T4 concentrations were deter-
mined for nine of the paired samples and plotted
against the corresponding level of total PBDEs in
each sample.
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BZoeller and Crofton 2000). Hallgren et al.
(2001) demonstrated a dose-related reduction in
both total T4 and free T4 concentrations in mice
and rats exposed to PBDEs. It is likely that
PBDEs or their metabolites displace thyroid
hormones from the serum binding protein
transthyretin, thereby allowing increased metab-
olism of the hormone (Hallgren and Darnerud
2002). In the present study, there was no appar-
ent association between serum concentrations of
PBDEs and thyroid hormones; however, the
sample size may have been too small to detect
such a relationship in a human population.
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